论文部分内容阅读
目的对他汀类药物调脂治疗冠状粥样硬化性心脏病的临床应用情况及获得的疗效进行深入探讨。方法选取我院2015年8月~2017年1月收治的冠状粥样硬化性心脏病患者78例作为该次应用研究的主体,随机双盲分组为应用1组和应用2组,各39例。给予应用1组常规冠心病的治疗操作;并基于应用1组的治疗操作基础上,对应用2组实施他汀类药物调脂治疗措施,对比两组用药治疗前后血脂水平的变化情况,以及症状趋好改善的效果。结果最后统计获得,应用2组的总用药有效率为94.87%(37/39)明显高于应用1组的82.05%(32/39),差异有统计学意义(P<0.05);经检测血脂四项指标水平,对比治疗前的检测数据,组间比较,差异无统计学意义(P>0.05);而对比治疗后的应用2组的改善程度要明显好于应用1组,各指标间的比较,差异有统计学意义(P<0.05)。结论基于常规治疗操作,对冠状粥样硬化性心脏病患者应用他汀类药物进行积极的调脂治疗,可有利于尽早减缓患者的动脉粥硬化病症,更可起到显著降脂的防治效果,此类药物具有颇高的应用安全性,可在临床广泛推广其应用。
Objective To investigate the clinical application of statins lipid-lowering therapy on coronary atherosclerotic heart disease and its curative effect. Methods Seventy-eight patients with coronary atherosclerotic heart disease admitted from August 2015 to January 2017 in our hospital were selected as the subjects of this study. Randomized double-blind grouping consisted of one group and two groups, 39 cases in each group. Given a group of conventional coronary heart disease treatment operation; and based on the application of a group of treatment based on the application of two groups of statins lipid-lowering treatment measures, compared two groups before and after treatment of blood lipid levels, and the trend of the trend Good effect of improvement. Results The final statistics showed that the total effective rate of the two groups was 94.87% (37/39), which was significantly higher than 82.05% (32/39) of the first application group, the difference was statistically significant (P <0.05) There was no significant difference between the two groups (P> 0.05), while the improvement of the two groups after application of contrast treatment was obviously better than that of the application group 1, and there was no significant difference between the two groups The difference was statistically significant (P <0.05). Conclusion Based on routine treatment, statin therapy for patients with coronary atherosclerotic heart disease may be beneficial in reducing atherosclerosis in patients with early onset of atherosclerosis as well as in the prevention and treatment of significant lipid lowering. Class of drugs with high application safety, can be widely promoted in clinical applications.